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CT-011, ANTI PD-1 ANTIBODY, ENHANCES EX-VIVO T CELL RESPONSES
TO AUTOLOGOUS DENDRITIC/MYELOMA FUSION VACCINE DEVELOPED
FOR THE TREATMENT OF MULTIPLE MYELOMA
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Vasir, B.2, Wu, Z.2, Zarwan, C.1, Schickler, M.3, Rotem-Yehudar, R.3,
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We have developed a cancer vaccine in which autologous mye-
loma cells are fused with dendritic cells (DCs) resulting in the pre-
sentation of tumor antigens in the context of DC mediated
costimulation. In animal models, vaccination with fusion cells re-
sults in eradication of established tumor, and in clinical trials,
both immunologic and clinical responses have been observed.
However, response to vaccination may be muted by inhibitory sig-
nals such as the PD1/PDL1 pathway which blunt activated T cell
responses. In this study, we evaluated expression of PD1 on T cells
derived from patients with multiple myeloma (MM), and PDL1
expression on primary myeloma cells and DC/MM fusions. We
evaluated the effect of PD-1 blockade on T cell response to
DC/MM fusion cell vaccination in vitro. Tumor cells were ob-
tained from bone marrow aspirates of MM patients. Nonadherent
peripheral blood mononuclear cells (PBMCs) obtained from pa-
tients with MM and normal volunteers were cultured in RPMI
supplemented with 10U/ml IL-2, and expression of PD-1 on
CD4 +T cells was assessed by flow cytometry. DCs were gener-
ated from adherent PBMCs cultured with rhIL-4, GM-CSF and
TNFa and fused with MM cells by coculture in 50% solution of
PEG. T cells were stimulated by DC/MM fusions in the presence
or absence of PD-1 blockade. We demonstrate that PD-1 expres-
sion is markedly upregulated on T cells in patients with advanced
MM. As compared to a control population in which mean levels of
PD-1 expression was 6% (n5 7), mean expression in patients with
MM was 20% (n5 9). Mean expression of PDL-1 was 66% on pa-
tient derived MM cells (n5 3) and. 90% on DC/MM fusions
(n5 2), which potentially provides an inhibitory signal dampening
fusion mediated immunologic response. We examined the effect of
PD-1 blockade on T cell response to DC/MM fusions ex vivo. En-
hanced fusion mediated stimulation of T cells was noted in the
presence of anti-PD-1, resulting in a greater than 5 fold increase
in T cell proliferation. Interferon gamma secretion by CD4 +T
cells in response to stimulation by DC/MM fusions increased
from 4% to 11% in the presence of PD1 blockade, while IL-10
secretion decreased from 6.5% to 3.5%. In summary, we demon-
strate that PD-1 expression is increased in T cells of MM patients,
and PD-1 blockade enhances activated T cell responses following
stimulation with a DC/MM fusion vaccine. A clinical trial in which
MM patients are treated with DC/MM fusions in conjunction with
anti-PD1 is planned.213
CYTOKINE LEVELS IN PATIENTS WITH PLASMA CELL DISORDERS (PCD)
UNDERGOING PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT)
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Kumar, S.K.1, Dingli, D.1,2, Engebretson, A.1, Tong, C.2,
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Background:We reported increased rates of engraftment syndrome
(ES) and associated morbidity in POEMS patients undergoing
PBSCT. The condition is successfully treated with early institution
of corticosteroids. We postulated that the high rates of ES in these
patients relates to their pre-existing aberrant cytokine milieu.
Methods:To test this hypothesis, we prospectively collected plasma
samples from patients undergoing PBSCT on day -2, 1, 4, 7, 10, 17
and 20. Charts were abstracted independent of knowledge of cyto-
kine information. Cytokine levels were run using BioSource Multi-
plex Bead Immunoassays Platform (Human cytokine 30-PLEX)–
30 different human cytokines, chemokines and growth factors. ES
was defined according to published criteria by Maiolino et al.
(BMT 2003) allowing for more liberal time relative to neutrophil en-
graftment.Results: A total of 18 patients were sampled: 9 POEMS, 4 multiple
myeloma (MM), and 5 amyloidosis (AL). Baseline characteristics are
summarized in Table 1. POEMS patients had higher median pre-
transplant levels of IL-4 (14.9 v 2.9 pg/mL p50.03), IL-10 (14.3 v
10.7 pg/mL, p5 0.004), EGF (31.7 v 0.0 pg/mL, p5 0.001), and
IFN-a (39.4 v 0.0 pg/mL, p5 0.01) than the patients with the other
PCDs. IP-10 was lower in POEMS patients (21.7 vs 43.1 pg/mL
p5 0.02). Day -2 plasma VEGF level was not significantly higher
in POEMS patients presumably since 67% of them received chemo-
therapy prior to PBSCT. Five patients developed ES – 2 POEMS, 2
AL and 1 MM – at a median of 10 days (range 8-13). Lower levels of
IL-1Ra and IL-15 post-transplant were associated with increased
risk of ES, p\0.05. Delayed engraftment of neutrophils correlated
with higher levels of IL-13 and EGF pre- and post-transplant.
Conclusion: These data are provocative in that they demonstrate
that prior to transplantation, the cytokine milieu differs between
POEMS patients and those with other PCDs, that EGF and IL-13
may predict for delayed engraftment, and that lower levels of IL-
1Ra and IL-15 may be associated with increased risk of ES. Larger
numbers of patients will be required to validate our findings.
Patient Characteristics
POEMS non-POEMS
(n5 9) (n5 9)% %Age in years, median (range) 52 (35-68) 62 (50-70)
Gender, M 44 89
Caucasian race 67 89
KPS, median (range) 70 (50-80) 90 (70-100)
Polyneuropathy 100 0
Organomegaly 78 11
Endocrinopathy 100 11
Skin Involvement 78 0
Extravascular fluid overload 100 44
Sclerotic bone lesions 67 0
Castleman’s dz 56 0
Splenomegaly 56 0
Papilledema 22 0
Prior treatments, median (range) 2 (1-4) 1 (0-7)
Chemo prior to transplant 67 78
Conditioning, Mel 200 67 78
Mobilization, G alone 89 67
CD34 infused, (x106/kg), median
(range)
3.88 (2.9-14.6) 4.93 (3.45-7.49)Engraftment syndrome 22 33
Engraftment*, days, median (range)
ANC. 500/uL 15 (13-19) 13 (12-15)
Platelets. 20/uL 11 (0-20) 13 (11-20)
Platelets. 50/uL 14 (12-27) 15 (12-25)*two non-POEMS patients died prior to platelet engraftment214
A NOVEL HAPLO-IDENTICAL ADOPTIVE CTL THERAPY AS TREATMENT
FOR EBV-ASSOCIATED LYMPHOMA AFTER STEM CELL TRANSPLANTA-
TION
Uhlin, M.1, Okas, M.1, Gertow, J.1, Uzunel, M.1, Brismar, T.2,
Mattsson, J.1 1Karolinska University Hospital Huddinge, Stockholm,
Sweden; 2Karolinska University Hospital Huddinge, Stockholm, Sweden
Epstein-Barr virus (EBV) related malignancies such as post-trans-
plant lymphoproliferative disease (PTLD) are severe complications
after allogeneic stem cell transplantation (SCT) and solid organ
transplantation. In immune suppressed transplant recipients the ac-
tivity of EBV-specific CTLs are often decreased or absent which
leads to an increased risk of developing PTLD. If primary treatment
modalities of PTLD fail, the most efficient way of treating the ma-
lignancy is adopting EBV-specific CTLs from the donor or, more
recently, third-party donors. This is however both time-consuming
and expensive and often it is too late to administer cells to the patient.
S238 Poster Session IWe have for the first time, using a rapid isolation protocol of EBV-
specific T cells, treated and cured a patient suffering from PTLD
with multiple associated tissue lesions, using her haplo-identical
mother as a donor. This treatment approach paves way for a new pos-
sibility to within days treat patients with life-threatening EBV-asso-
ciated malignancies.215
ALLOGENEIC STEM CELL TRANSPLANTATION WITH REDUCED INTEN-
SITY CONDITIONING AS TREATMENT FOR MATURE T-CELL LYMPHOMAS
Delioukina, M.L.1, Palmer, J.2, Zain, J.M.3, Tsai, N.2, Forman, S.1
1City of Hope National Medical Center, Duarte, CA; 2City of Hope
National Medical Center, Duarte, CA; 3NYU Langone Medical Center,
New York, NY
Background: For aggressive lymphomas a T-cell phenotype confers
a poor prognosis. Current therapeutic strategies for T-cell non-
Hodgkin lymphoma (NHL) are poorly defined. Allogeneic stem
cell transplantation (Allo-HCT) is a potentially curative option but
associated with high non-relapse mortality (NRM). Reduced inten-
sity conditioning (RIC) is designed to minimize NRM while using
the benefits of the graft-versus-lymphoma effect. Here we report ret-
rospective analysis of patients with T-cell NHL who underwent
Allo-HCT with RIC using fludarabine and melphalan.
Patients andMethods:A consecutive case-series of 27 patients with
mature T-cell NHLwere included. All patients underwent RICwith
fludarabine and melphalan. Histologies included: PTCL NOS
(n5 5); AILD (n5 3); ALCL (n5 2; both alk+); rare histologies
(n5 6) (NK/T cell, enteropathy type, hepatosplenic); and cutaneous
T-cell lymphomas (n5 11). Most patients (n5 18, 67%) had ad-
vanced disease at the time of transplant: relapse/induction fail-
ure5 17, progression5 1. The rest of the patients were in
CR15 1, CR25 5, PR5 3. The median age was 50 years (range:
19-68), 74% were male (n5 20). The time from diagnosis to trans-
plant for majority of the patients (n5 20, 74%) was more than one
year. The median number of prior regimens was 4 (range: 1-9);
one patient had a prior autologous transplant. All patients received
stem cells, 56% from HLA-matched sibling and 44% from matched
unrelated donor. 18 patients (67%) received GVHD prophylaxis
with sirolimus/tacrolimus, while 9 patients (33%) received cyclo-
sporine/cellcept based prophylaxis.
Results: The median follow-up for the 16 (59%) surviving pa-
tients was 24.2 months (range: 5.6-95.3). Day 100 mortality
was 22% (n5 6). There were a total of 11 deaths; 5 from dis-
ease progression/relapse and 6 from non-relapse causes. 13 pa-
tients (48%) experienced acute GVHD: grade I5 4, grade
II5 5, grade IV5 4. Among the 17 patients who are evaluable
for chronic GVHD, 11 (63%) patients developed an extensive
GVHD. The 2-year probability of overall (OS) and disease-
free (DFS) survival were 55% (95%CI: 43-65%) and 43%
(95%CI: 34-52%) respectively. The relapse/progression and
NRM rates at 2 years were 37% (95%CI: 26-52%) and 28%
(95%CI: 16-46%) respectively.
Conclusion: The overall results show that good long term survival
rates and disease control can be achievedwith acceptable non-relapse
mortality in patients with mature T-cell lymphomas using reduced
intensity conditioning.216
THE IMPORTANCE OF TIMING OF HEMATOPOIETIC STEM CELL TRANS-
PLANTATION (HSCT) IN PATIENTS WITH T-CELL LYMPHOMAS (T-NHL)
Ritter, E.M.1, Zamkoff, K.W.2, Levitan, D.A.2, Hurd, D.D.2 1Wake
Forest University School of Medicine, Winston-Salem, NC; 2Wake Forest
University School of Medicine, Winston-Salem, NC
Patients (pts) with T-NHL have a poor prognosis with standard
chemotherapy. HSCT have been used in their management but
the most appropriate time for HSCT is not clear. We previously re-
ported the poor outcome of pts with ALK negative (anaplastic lym-
phoma kinase) anaplastic large cell lymphoma (ALCL) having
HSCT after first recurrence (Zamkoff et al, BMT 33:635-8,2004).To further investigate outcomes of pts transplanted for T-NHL,
we retrospectively analyzed 33 pts undergoing autologous HSCT
from August 2000 to July 2009. 23 were male, 10 female; median
age was 53.2 (29 -73) years at time of HSCT. Subtypes of T-NHL
included Alk negative ALCL (9) and Alk positive ALCL (1); periph-
eral T-Cell (PTCL), not otherwise specified (11); Angioimmuno-
blastic (AILT) (9); Nasal NK/T (2) and cutaneous T-cell (CTCL)
(1). 6 pts were in their first complete remission (CR1), 1 in CR1 un-
confirmed (CRU1), 10 in first partial remission (PR1), 9 in first re-
lapse (Rel1) with 8 sensitive and 1 refractory, 3 in CR2, and 4 in
second or later sensitive relapse (Rel2+). Preparative regimens for
HSCT included Cy/TBI (13) or Cy/etoposide/TBI (9), Bu/Cy (6),
CBV (4), and BEAM (1).
Among the 12 pts in CR1/CRU1 or PR1\200 days from diagno-
sis (Group 1), there were 2 with Alk negative ALCL, 5 PTCL, 4
AILT, and 1 Nasal NK/T. Among the 21 pts (Group 2), there
were 7 with Alk negative ALCL, 1 Alk positve ALCL, 6 PTCL, 5
AILT, 1 Nasal NK/T, and 1 CTCL.
With a median follow-up of 17.6 (0.4-84.0) months post
HSCT, the overall survival (OS) is estimated to be 52% and pro-
gression free survival (PFS) is 45%. 16 pts have expired. Causes of
death include relapse (12), transplant related mortality (1), second
malignancy (1), and unknown (2) since no MD follow-up records
available.
Among the 17 surviving pts, 10 were among the 12 pts in
Group 1. For this group, the OS is 83% with a PFS of 75% at
a median follow-up of 18.6 (0.7-60.5) months. 7 additional pts
survive among the Group 2 pts; their OS is 33% and PFS is
29% at a median follow-up of 15.2 (13-84) months. In Group
2, surviving pts include 1 of 3 transplanted in CR2; 6 of 13 trans-
planted in Rel1 or Rel2+ and 0 of 5 in PR1 transplanted .200
days from diagnosis.
In summary, this data would suggest an improved outcome for
HSCT in pts withT-NHLwhen applied earlier in the course of their
disease. Such a strategy should be evaluated in a larger prospective
trial of HSCT in CR1/PR1 to evaluate the efficacy and safety across
the various subtypes T-NHL.217
PREFERENCE OF PATIENTS AND PHYSICIANS CONCERNING TREATMENT
OPTIONS FOR RELAPSED FOLLICULAR LYMPHOMA: A DISCRETE CHOICE
EXPERIMENT
Shafey, M.1, Stewart, D.A.2, Do, T.3, Lupichuk, S.2 1University of Cal-
gary, Calgary, AB, Canada; 2Tom Baker Cancer Centre, Calgary, AB,
Canada; 3Abbotsford Cancer Centre, BC Cancer Agency, Abbotsford,
BC, Canada
Background: Patients with symptomatic relapsed follicular lym-
phoma, together with their physicians, must choose between a va-
riety of treatment options. The purpose of this study was to elicit
relative preferences for attributes associated with different treat-
ment options amongst lymphoma patients in Alberta, and lym-
phoma-treating physicians in Canada, using a discrete choice
experiment (DCE).
Methods: 180 patients aged 18-65 years and 252 physicians re-
ceived background information and a questionnaire containing
the DCE. Treatment administration, toxicity, average remission
length, and cost were the attributes evaluated for four treatment
options: standard chemotherapy (CT), radioimmunotherapy
(RIT), high-dose chemotherapy and autologous (AUTO) or allo-
geneic (ALLO) stem cell transplantation. In a series of multiple
choice questions, respondents were asked to choose between
two unlabeled treatment options, described according to the attri-
butes where the attribute levels were different for each option.
The DCE was analyzed using a random effects logit model. Mar-
ginal rates of substitution calculated from regression coefficients
provided information about preference for the treatment attri-
butes.
Results: 81 patients (45%) and 48 physicians (19%) completed the
questionnaire. Responding patients had a mean age of 54.7 years
and were on average 4.4 years from initial diagnosis. 93% of patients
